Skip to content

Application of genetic testing in judging the benign and malignant thyroid nodules of Bethesda I, II and III

Application of genetic testing in judging the benign and malignant thyroid nodules of Bethesda I, II and III

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030473
Enrollment
Unknown
Registered
2020-03-03
Start date
2020-02-26
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Sponsors

Southwest Hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 70 years; 2. Patients who are highly suspected of malignant thyroid nodules by imaging but whose pathological results after FNA suggest Bethesda I, II, III; 3. Other general condition is good: physical condition score 0 to 2 points; 4. Hematology: white blood cells >= 3.5 x 10^9 / L, platelets >= 100 x 10^9 / L, neutrophils >= 2.0 x 10^9 / L, hemoglobin >= 95g / L. 5. Liver function: serum bilirubin is 1.5 times the maximum normal value; ALT and AST are 1.5 times the maximum normal value. 6. Renal function: creatinine clearance >= 45ml / min. 7. Coagulation function: APTT, PT, FIB, TT showed no obvious abnormalities. 8. Heart function: Basically normal. 9. Informed consent is required, and is willing to cooperate with the project for clinical follow-up. 10. Is willing to cooperate with the provision of FNA test samples, patient imaging and postoperative pathological routines and other related medical records, and is willing to use the test data for scientific research in clinical institutions.

Exclusion criteria

Exclusion criteria: 1. Have other malignancies at the same time; 2. At the discretion of the investigator, the patient suffers from other major diseases that may affect follow-up and short-term survival; 3. Any social / psychological issues where the patient judges that the patient is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
BRAF gene;SEN, SPE, ACC, AUC of ROC, NPV, PPV;

Countries

China

Contacts

Public ContactXiaowei Qi

Southwest Hospital, Army Medical University

qxw9908@foxmail.com+86 13527545423

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026